NDAINJECTIONINJECTABLE
Approved
Dec 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
CISPLATIN (cisplatin) by R-Pharm US is cross-links. Approved for non-small cell lung cancer, head and neck cancer, small cell lung cancer and 3 more indications. First approved in 1978.
Drug data last refreshed Yesterday
Mechanism of Action
cross-links. This interferes with normal transcription and/or DNA replication mechanisms and triggers cytotoxic processes that lead to cell death.
Pharmacologic Class:
Platinum-based Drug
Indications (6)
Worked on CISPLATIN at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.